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Introduction:  The  purposes  of  this  study  are  the characterization  the  lipid proﬁle  and  the  suitability  of
the  statins  treatment  according  to  the  cardiovascular  proﬁle.  Also,  in statin-treated  patients,  we aim to
determine  the  prevalence  of persistent  lipid  abnormalities.
Material  and  methods:  Observational  and  retrospective  study  of outpatient  diabetic  patients  of a hospital
consultation,  between  Jun/2014  and  Jun/2015.
Results: Of  the 199 diabetic  patients  included,  58.6%  were  treated  with  statins  and  only 13.9% were  treated
with  statin  dose  adequate  for its cardiovascular  proﬁle.  The  patients  without  overt  cardiovascular  dis-
ease  had  higher  total  cholesterol  (178.0  vs  157.5 mg/dl;  p =  0.003),  HDL-C  (51.0  vs 43.0 mg/dl;  p =  0.005),
LDL-C  (97.0  vs  79.0  mg/dl;  p = 0.004)  and  non-HDL-C  (127.0  vs  112.5  mg/dl;  p  = 0.04)  and higher preva-
lence  of patients  who  achieved  HDL-C  goals  (64.3  vs  33.3%;  p < 0.0001).  Almost  half  of statin-treated
patients  (46.8%)  failed  to  achieve  the  LDL-C  goals,  35.8%  and  51.6%  failed  the  triglycerides  and  HDL-C
goals,  respectively.  Only  11.7%  achieved  all three  goals.  In  statin-treated  patients,  we  found  a statistically
signiﬁcant  difference  between  patients  with  and  without  cardiovascular  disease  on  the  prevalence  of
patients  reaching  the  target  HDL-C  (68.1  vs  35.4%;  p =  0.001).  There  were  no  differences  in the prevalence
of  patients  who  achieved  LDL-C  and  triglyceride  goals.
Discussion/conclusion:  There  is  a suboptimal  utilization  of  statins  and  a substantial  percentage  of  diabetic
patients  that  do  not  achieve  the  therapeutic  goals.  We  emphasize  the  need  for an  effort  to  optimize  the
lipid proﬁle  of  diabetics  in order  to contribute  to reducing  the  prevalence  of cardiovascular  diseases  in
this population.
© 2016  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
Espan˜a,  S.L.U.  This  is an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Perﬁl  lipídico  e  persistência  de  anomalias  lipídicas  em  doentes  diabéticos  –
um  estudo  retrospetivo
alavras-chave:
iabetes mellitus
islipidemia
statinas
r  e  s  u  m  o
Introduc¸ ão:  Os objetivos  são  a caracterizac¸ ão do perﬁl  lipídico  e a avaliac¸ ão do  tratamento  com  estati-
nas  de  acordo  com  o perﬁl  cardiovascular.  Adicionalmente,  pretendemos  determinar  prevalências  de
anomalias  lipídicas  persistentes  nos doentes  tratados  com  estatinas.
Materiais  e  métodos:  Estudo  observacional  e  retrospetivo  de  diabéticos  acompanhados  numa  consulta
hospitalar  entre  06/2014  e 06/2015.
Resultados:  Dos  199  doentes,  58,6%  estavam  tratados  com  estatinas  e 13,9%  estavam  tratados  com  doses
de estatinas  adequadas  para  o perﬁl  cardiovascular.  Os  doentes  sem  doenc¸ a cardiovascular  (DCV)  tinham
níveis mais  elevados  de  colesterol  total  (178,0  vs.  157,5  mg/dl;  p =  0,003),  HDL-C  (51,0  vs.  43,0  mg/dl;
p  =  0,005),  LDL-C  (97,0  vs. 79,0  mg/dl;  p =  0,004),  e não-HDL-C  (127,0  vs.  112,5  mg/dl;  p =  0,04)  e uma
maior  prevalência  de  doentes  que  alcanc¸ aram  metas  de  HDL-C  (64,3  vs. 33,3%;  p  < 0,0001).  Quase  metade
dos  doentes  tratados  com  estatinas  (46,8%)  não  atingiram  o  valor  alvo  de  LDL-C,  35,8  e 51,6%  falharam
as  metas  de  HDL-C  e de  triglicerídeos,  respetivamente.  Apenas  11,7%  atingiram  todos  os  3 objetivos.  Nos
∗ Corresponding author.
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doentes  tratados  com  estatinas,  encontramos  diferenc¸ a estatisticamente  signiﬁcativa  entre  os  doentes
com e  sem  DCV,  sobre  a prevalência  de  atingimento  do alvo  HDL-C  (68,1  vs.  35,4%,  p  = 0,001).  Não  houve
diferenc¸ as na  prevalência  de doentes  que  atingiram  os  objetivos  de  LDL-C  e triglicerídeos.
Discussão  e  conclusão:  Veriﬁca-se  uma  utilizac¸ ão subótima  das  estatinas  e  uma  percentagem  substancial
de diabéticos  que  não  alcanc¸ am  os  objetivos  terapêuticos.  Salienta-se  a necessidade  de  um  esforc¸ o para
otimizar  o perﬁl  lipídico  dos  diabéticos  de  forma  a contribuir  para  a diminuic¸ ão da  prevalência  de  DCV
nesta populac¸ ão.
©  2016 Sociedade  Portuguesa  de Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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Cardiovascular disease (CVD) is the leading cause of death
mong adult diabetic patients.1 Although the multifactorial etiol-
gy of atherosclerotic vascular disease, dyslipidemia is a common
nd an important predictor of cardiovascular risk.2 Dyslipidemia
s usually present at diagnosis of type 2 diabetes and persists
egardless of the treatment of hyperglycemia. The main therapy
oal in the management of dyslipidemia is to decrease the levels
f LDL-cholesterol (LDL-C) and other apolipoprotein-B-containing
ipoproteins, which is primarily achieved with dietary modiﬁca-
ions and statins.3,4
Data from randomized controlled trials of statin therapy show
ighly signiﬁcant reductions in the incidence of major CVD events
n diabetic patients, with or without established CVD. Moreover,
he reductions in major CVD events are proportional to the reduc-
ion in LDL cholesterol. Despite the widespread evidence of the
eneﬁts of lipid-lowering treatment, particularly with statins, for
educing cardiovascular disease and mortality in diabetic patients,
 considerable proportion of diabetic patients do not achieve the
herapeutic goals in LDL cholesterol.5,6
The aim of this study is to characterize lipid proﬁle of diabetic
atients, according the presence or absence of previous cardiovas-
ular event and the evaluation of the suitability of the treatment
ith statins according to the cardiovascular proﬁle. Additionally,
ur purpose is to determine in the statin-treated patients, the
revalence of persistent lipid abnormalities.
aterial and methods
ata sources and subjects
This article describes an observational, analytical and retrospec-
ive study of outpatient diabetic patients followed at Educational
herapy of Diabetes Consultation (CTED) in Centro Hospitalar do
orto (CHP), between June 2014 and June 2015. CTED is a mul-
idisplinary consultation composed of endocrinologists, nurses,
utritionists, psychologists and podiatrists. The main purpose of
his consult is diabetes self-management education and support.
he patients are referenced to this consult by family physician or
y another specialty consultation in HSA.
Outpatients eligible for inclusion were age ≥18 years old.
atients were excluded if they were type 1 diabetic and if was
mpossible to obtain the ﬁle of the patient. The source of infor-
ation was electronic or paper ﬁle.
ata collection
Data were collected from medical records and clinical exam-
nation at the time of the consults. Demographics (age and
ender) and anthropometric variables [weight, height and body
ass index (BMI)] were recorded at ﬁrst visit, as well as gly-
osylated hemoglobin (DCA2000 method). Lipid proﬁle [totalOpen  Access  sob  uma  licenc¸ a CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
cholesterol (TC), triglycerides (TG), LDL-C, HDL-cholesterol (HDL-
C) and apolipoprotein B (apoB)] were obtained on the second visit.
The measurements were made in the same laboratory, by standard
hospital assays – CT, HDL-C and TG through enzymatic meth-
ods (Roche®) in freshly drawn lithium-heparin plasma samples.
The value of LDL-C was calculated using the Friedewald equation
(LDL-C = TC-HDL-C-[TG/5]), if TG levels <400 mg/dl and measured
directly at higher levels. Non-HDL cholesterol (non HDL-C) was also
calculated (TC-HDL-C). Apolipoproteins were measured through
immunoturbidimetric assays. Because of its inﬂuence on lipid pro-
ﬁle, we excluded thyroid dysfunction in all patients through TSH
measurement by electrochemiluminescence.
The presence of cardiovascular risk factors (smoking, hyper-
tension, dyslipidemia and physical inactivity), of diabetic kidney
disease and history of cardiovascular disease (ischemic heart dis-
ease, cerebrovascular disease and peripheral artery disease) were
registered.
Deﬁnition of dyslipidemia
To determine the persistence of lipid abnormalities, in terms of
dyslipidemia treatment and goals of lipid levels, it was applied the
American Diabetes Association (ADA) recommendations of 2014.
Accordingly, patients without overt CVD the goal of LDL-C is less
than 100 mg/dl, and in individuals with overt CVD the goal of LDL-
C is less than 70 mg/dl. Although the LDL-target statin therapy is
the preferred strategy, additional targets are triglyceride levels less
than 150 mg/dl and HDL-C superior to 40 or 50 mg/dl, in men and
women, respectively.7
The lipid levels goals correspond to a range of values deﬁned
by an upper limit without a lower limit. Although the term target
is commonly used interchangeably, achieving targets could result
in the undertreatment of many patients who  could beneﬁt from
having LDL-C, triglyceride values below the target values or HDL-C
above the target value.
To analyze the suitability of the dose of statins were used
the recommendations of the ADA in 2015. Therefore, diabetic
patients were divided in groups considering the age and the pres-
ence or absence of overt CVD [previous cardiovascular events or
acute coronary syndromes] and cardiovascular (CV) risk factors
[LDL ≥ 100 mg/dl, high blood pressure, smoking, overweight or obe-
sity]. Patients of all ages with diabetes and overt CVD should be
medicated with an high-dose statin. Patients with diabetes under
40 years of age and with additional CVD risk factors, it should be
considered using moderate or high-dose statin. For patients with
diabetes aged 40–75 years without additional CVD risk factors,
it should be considered using moderate-dose statin. For patients
with diabetes aged 40–75 years with additional CVD risk factors,
it should be considered using high-dose statin. For diabetics over
75 years old without additional CVD risk factors, it should be con-
sidered using moderate-dose statin therapy. And for patients over
75 years with additional CVD risk factors, it should be considered
using moderate or high-dose statin therapy.8
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Table 1
The characteristics of study population (n = 199).
Variables Results
Age (years), mean ± SD 59.0 ± 9.6
Male, %, (95% CI), (n/N) 56.8 (47.8–63.1) (113/199)
T2DM, %, (95% CI), (n/N) 94.0 (89.8–96.8) (187/199)
HbA1c (%), median; IQR 8.0; 2.2
Current smoker, %, (95% CI), (n/N) 9.7 (3.8–12.7) (19/196)
Sedentary lifestyle, %, (95% CI), (n/N) 69.4 (61.1–75.8) (136/196)
BMI, median; IQR 28.7; 6.3
Overweight (BMI ≥ 25 and <30), %,
(95% CI), (n/N)
38.2 (30.6–45.9) (65/170)
Obesity (BMI ≥ 30), %, (95% CI), (n/N) 38.8 32.5–47.8) (66/170)
Dyslipidemia, %, (95% CI), (n/N) 77.7 (75.8–87.9) (153/197)
Hypertension, %, (95% CI), (n/N) 70.2 (66.2–80.9) (139/198)
CAD, cerebrovascular disease and/or
PAD, %, (95% CI), (n/N)
33.3 (28.0–42.7) (66/198)
Statin-treated, %, (95% CI), (n/N) 58.6 (54.8–69.4) (109/186)
T
C
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The statins were classiﬁed in high-intensity and moderate-
ntensity according to the potency for lowering LDL-C. High-
ntensity statins lowers LDL-C by 50% (atorvastatin 40 mg,
torvastatin 80 mg,  rosuvastatin 20 mg  and rosuvastatin 40 mg).
oderate-intensity statins lowers LDL-C 30–50% (atorvastatin
0 mg,  atorvastatin 20 mg,  rosuvastatin 5 mg,  rosuvastatin 10 mg,
imvastatin 20 mg,  simvastatin 40 mg,  pravastatin 40 mg,  pravas-
atin 80 mg,  lovastatin 40 mg,  ﬂuvastatin XL 80 mg,  ﬂuvastatin
0 mg  bid, pitavastatin 2 mg,  pitavastatin 4 mg).8
tatistical analysis
Continuous variables are expressed as the mean and
tandard deviation (SD) or median and interquartile range (IQR)
25th–75th percentile), according to the distribution of variables.
ge was the only continuous variable with a normal distribu-
ion and was expressed as mean and SD. The others continuous
ariables had a non-normal distribution and were expressed as
edian and IQR. Categorical variables are expressed as frequen-
ies, percentages and conﬁdence interval of 95% (95% CI). Group
omparisons were made using the Mann–Whitney U test or the
ilcoxon rank-sum test for continuous variables and the chi-
quare (2) test for categorical variables. Statistical signiﬁcance
as deﬁned at p < 0.05. Statistical analysis was performed using
PSSTM software version 20.
esults
The study included 199 diabetic patients with a mean age of
9.0 ± 9.6 years and with a preponderance (56.8%; n = 113) of males.
n this population, type 2 diabetes was the predominant type of
iabetes (94.0%; n = 187) and the median HbA1c were 8.0% IQR 2.2.
he majority of these patients was overweight (BMI ≥ 25) (77.0%;
 = 131) and had a sedentary lifestyle (69.4%; n = 136). Also, we
ound a high prevalence of dyslipidemia (77.7%; n = 153) and hyper-
ension (70.2%; n = 139). More than a third (33.3%; n = 66) had a
revious cardiovascular event and 58.6% (n = 109) were treated
ith statins (Table 1).
The study population was divided in two groups according to the
resence or absence of previous cardiovascular event, as shown in
able 2. There were no differences between the groups in terms of
ge, sex, metabolic control (HbA1c) and prevalence of obesity. The
roup of patients with previous cardiovascular events had higher
revalence of dyslipidemia (87.7 vs 72.7%; p = 0.02), hypertension
87.9 vs 61.4%; p < 0.0001) and was more frequently statin-treated
87.5 vs 43.4%; p < 0.0001).
The group of patients without overt CVD had higher TC (178.0 vs
57.5 mg/dl; p = 0.003), HDL-C (51.0 vs 43.0 mg/dl; p = 0.005), LDL-C
able 2
haracteristics of the groups: with and without overt CVD.
Variables Overt CVD (n = 66) 
Age (years), mean ± SD 60.4 ± 9.2 
Male,  %, (95% CI) (n/N) 54.5 (37.8–68.2) (36/66) 
T2DM, %, (95% CI) (n/N) 98.5 (92.5–100.0) (65/66) 
HbA1c (%), median; IQR 8.1; 2.2 
Current smoker, %, (95% CI) (n/N) 10.6 (2.5–21.7) (7/66) 
Sedentary lifestyle, %, (95% CI) (n/N) 74.2 (69.8–93.0) (49/66) 
BMI,  median; IQR 28.9; 6.5 
Overweight (BMI ≥25 and <30), %, (95% CI) (n/N) 46.6 (29.7–57.9) (27/58) 
Obesity (BMI ≥ 30), %, (95% CI) (n/N) 41.4 (32.6–61.4) (24/58) 
Dyslipidemia, %, (95% CI) (n/N) 87.7 (81.8–98.0) (57/65) 
Hypertension, %, (95% CI) (n/N) 87.9 (81.8–98.0) (58/66) 
Statin-treated, %, (95% CI) (n/N) 87.5 (85.4–100.0) (56/64) 
MI: body mass index; CAD: coronary artery disease; CVD: cardiovascular disease; PAD: 
* Statistical signiﬁcance: p < 0.05.BMI: body mass index; CAD: coronary artery disease; PAD: peripheral artery disease;
T2DM: type 2 diabetes mellitus.
(97.0 vs 79.0 mg/dl; p = 0.004) and non-HDL (127.0 vs 112.5 mg/dl;
p = 0.04) and higher prevalence of patients who achieved HDL-C
goals (64.3 vs 33.3%; p < 0.0001), as demonstrated in Table 3. There
were no statistical differences on the median of the triglycerides
and of the apo-B.
A strong and positive correlation between apo-B and non-HDL-C
was veriﬁed (r = 0.87; p < 0.001).
The group of patients without overt CVD had signiﬁcantly higher
prevalence of patients that met  the HDL-C goals (64.3 vs 33.3%;
p < 0.0001). Although, we  found no statistical difference on preva-
lence of patients that met  the LDL-C and TG goals.
The study of suitability of the dose of the statin has shown
that there were no differences between the groups (14.1 vs 6.6%;
p = 0.095).
To evaluate the persistence of lipid abnormalities, the patients
were divided in statin-treated and non-statin treated.
In statin-treated patients, 13.9% were treated with statins with
adequate potency to their cardiovascular proﬁle. There were no
differences between the patients with and without overt CVD in
the adequacy of statin treatment (Table 4). Less than half (46.8%,
n = 44) failed to achieve the LDL-C goal. Half (51.1%; n = 48) and
35.1% (n = 33) of these patients failed to achieve HDL-C and TG
goals, respectively. Only 11.7% (n = 11) of these patients achieved
all three goals. In this group of patients, we found a statistically sig-
niﬁcant difference between those with and without cardiovascular
disease in HDL-C median level (43.0 vs 50.5; p = 0.003) and in the
prevalence of patients reaching the target of HDL-C (68.1 vs 35.4%;
p = 0.001). There were no differences in the prevalence of patients
who achieved LDL-C and triglyceride goals (Table 4).
Non-CVD (n = 132) All (n = 199) p Value*
58.2 ± 9.7 59.0 ± 9.6 0.1
58.3 (44.4–63.9) (77/132) 56.8 (47.8–63.1) (113/199) 0.6
91.7 (85.9–96.1) (121/132) 94.0 (89.8–96.8) (187/199) 0.4
8.0; 2.3 8.0; 2.2 0.5
9.2 (2.0–12.1) (12/130) 9.7 (3.8–12.7) (19/196) 0.8
66.9 (57.6–75.3) (87/130) 69.4 (61.1–75.8) (136/196) 0.3
28.6; 6.5 28.7; 6.3 0.08
33.3 (24.2–43.0) (37/111) 38.2 (30.6–45.9) (65/170) 0.09
37.8 (28.6–47.4) (42/111) 38.8 (32.5–47.8) (66/170) 0.7
72.7 (68.6–85.0) (96/132) 77.7 (75.8–87.9) (153/197) 0.02
61.4 (56.6–75.2) (81/132) 70.2 (66.2–80.9) (139/198) <0.0001
43.4 (36.3–55.8) (53/122) 58.6 (54.8–69.4) (109/186) <0.0001
peripheral artery disease; T2DM: type 2 diabetes mellitus.
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Table 3
Lipid proﬁle in diabetics with and without overt CVD.
Lipid proﬁle Overt CVD Non-CVD All p Value*
Total cholesterol (mg/dl), median; IQR 157.5; 51.8 178.0; 58.0 172.5; 58.5 0.003
Triglycerides (mg/dl), median; IQR 129.5; 99.8 113.0; 82.3 117.0; 85.3 0.3
HDL-C (mg/dl), median; IQR 43.0; 14.0 51.0; 24.0 47.0; 23.0 0.005
LDL-C (mg/dl), median; IQR 79.0; 45.0 97.0; 50.0 89.0; 49.5 0.004
Apo-B (mg/dl), median; IQR 82.0; 39.8 92.0: 33.0 90.0; 33.8 0.08
Non-HDL-C (mg/dl), median; IQR 112.5; 45.5 127.0; 53.0 117.0; 52.3 0.04
Patients at LDL-C goal,a %, 95% CI, (n/N) 39.6 (24.0–51.2) (21/53) 52.2 (39.6–61.2) (60/115) 48.2 (81/168) 0.13
Patients at TG goal,b %, 95% CI, (n/N) 63.0 (47.9–76.5) (34/54) 70.4 (61.1–80.4) (81/115) 67.6 (115/170) 0.3
Patients at HDL-C goal,c %, 95% CI, (n/N) 33.3 (18.4–44.9) (18/54) 64.3 (56.5–76.0) (74/115) 54.1 (92/170) <0.0001
Patients achieving all goals
(LDL-C, HDL-C and TG), %, 95% CI, (n/N)
5.7 (0.0–11.4) (3/53) 9.6 (3.2–14.9) (11/115) 8.3 (14/168) 0.4
Patients with adequate statin-treatment, %, 95% CI,
(n/N)
14.1 (4.5–23.9) (9/64) 6.6 (2.1 – 12.0) (8/121) 9.1 (17/186) 0.095
CVD: cardiovascular disease.
a LDL-C goal: <70 mg/dl and <100 mg/dl in patients with and without overt CVD, respectively.
b TG goal: <150 mg/dl.
c HDL-C goal: > 40 or 50 mg/dl, in men  and women, respectively.
* Statistical signiﬁcance: p < 0.05.
Table 4
Persistence of lipid abnormalities.
Lipid proﬁle Statin-treated p Value*
Overt CVD Non-CVD All (n = 109)
Adequate statin, % (n/N) 16.1 (6.5–26.0) (9/56) 11.5 (3.9–20.8) (6/52) 13.9 (5.4–13.4) (15/108) 0.5
Total  cholesterol (mg/dl), median; IQR 156.0; 58.0 172.0; 53.8 162.0; 48.0 0.13
Triglycerides (mg/dl), median; IQR 134.0; 96.0 126.5; 74.0 130.0; 84.0 0.4
HDL-C (mg/dl), median; IQR 43.0; 14.0 50.5; 18.8 45.0; 19.0 0.003
LDL-C  (mg/dl), median; IQR 77.5; 46.3 86.5; 45.8 83.0; 48.8 0.2
Apo-B  (mg/dl), median; IQR 82.0; 39.0 90.0; 25.0 85.0; 30.5 0.4
Non-HDL (mg/dl), median; IQR 113.0; 50.0 115.0; 46.5 113.0; 48.0 0.4
Patients not at LDL-C goal,a % (95% CI) (n/N) 56.5 (35.7–67.5) (26/46) 37.5 (24.3 – 52.4) (18/48) 46.8 (33.7–55.4) (44/95) 0.07
Patients not at TG goal,b % (95% CI) (n/N) 38.3 (24.1–55.6) (18/47) 33.3 (20.9–48.4) (16/48) 35.8 (26.0–46.9) (34/95) 0.6
Patients not at HDL-C goalc % (95% CI) (n/N) 68.1 (50.0–79.1) (32/47) 35.4 (22.0–50.0) (17/48) 51.6 (39.3–60.9) (49/95) 0.001
Patients achieving all goals (LDL-C, HDL-C and TG), % (n/N) 6.5 (0.0–16.7) (3/46) 16.7 (6.8–28.0) (8/48) 11.7 (5.7–19.8) (11/94) 0.1
CVD: cardiovascular disease.
a LDL-C goal: <70 mg/dl and <100 mg/dl in patients with and without overt CVD, respectively.
b
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c HDL-C goal: > 40 or 50 mg/dl, in men  and women, respectively.
* Statistical signiﬁcance: p < 0.05.
iscussion
As other similar published studies our study population
ncluded diabetic patients with a mean age in the sixties and with
 high prevalence of overweight, sedentary lifestyle, dyslipidemia
nd hypertension.9,10 Also, we found an elevated prevalence of
on-statin treated patients (56.8%).
The group of patients without overt CVD was more frequently
on-statin treated and had higher TC, LDL-C, HDL-C and non-HDL.
lso, there was a trend for statistical signiﬁcance to higher apo-B
evels.
In the Dyslipidemia International Study (DYSIS) the diabetics
ithout a previous CVD also had higher LDL-C and HDL-C.10 Those
acts may  reﬂect better lipid-focused treatment in patients with
 previous event of CVD. The group of patients without previous
VD had signiﬁcantly higher prevalence of patients that achieved
he HDL-C goals, and this is concordant with the ﬁndings of DYSIS.10
 higher level HDL-C in patients without overt CVD can be the
eﬂection of their cardioprotective effect.
In our study, half of the statin-treated diabetic patients (53.2%)
chieved LDL-C goals. This ﬁnding is similar to the analysis of Leiter
t al. and Feher et al., however are in contrast with the analysis of
ilva et al. of Portuguese subpopulation of the DYSIS (77.1%).9–11 We
eriﬁed that over one third (35.8%) did not achieved TG goals, half
51.6%) did not achieved HDL-C goals and only a minority (11.7%) of
atients achieved all three goals. In the Portuguese subpopulationanalysis of DYSIS the percentage of patients that not met  the TG
goals are similar (41.4%) but diverge on the percentage of patients
that failed the HDL-C goal (27.7%).9 In DYSIS, a quarter (25.9%) of
the diabetic patients and almost 20% (19.9%) did not achieve TG and
HDL-C goals, respectively, and 39% of the patients achieve all goals.
10 Feher et al. demonstrated that approximately half of the patients
who received statin monotherapy attained the treatment goals for
HDL-C and TG.11
When analyzing the suitability of the dose of the statin we ver-
iﬁed that there were no differences between the groups, although
with a tendency to signiﬁcance for the group with overt CVD. This
can be the expression, again, of a higher attention to lipid treatment
in patients with a previous event of CVD.
The vast majority of patients were treated with a dose of statin
non-adequate to their cardiovascular proﬁle. This observation must
be analyzed very carefully because the study included patients
observed from June 2014 to June 2015. As this recommendations
were published in November 2013 by the ACC/AHH and adopted
by ADA in January 2015, we  cannot make ﬁrm conclusions about
the suitability of statins dose, and this is a considerable limitation
of the study.Limitations
This study reﬂects a small sample of patients evaluated in the
CTED, analyzed retrospectively and we  did not evaluate long-term
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and Canada: results of the Dyslipidaemia International Study. Diabet Med.A.M. Monteiro, I. Palma / Rev Port Endo
utcomes. In addition, we lack data of adherence to treatment
egime or contraindications to statin therapy.
onclusion
Several clinical studies have demonstrated evidence supporting
he beneﬁcial effects of statins therapy in patients for both pri-
ary and secondary prevention of CVD events and death. Also,
ecommendations of treatment and management of dyslipidemia
re wide spread to guide medical decision. Despite those facts, evi-
ence has shown, in concordance to our results, a suboptimal use of
ipid-modifying therapies and a substantial percentage of diabetic
atients that do not achieve the therapeutic goals. We  emphasize
hat is necessary an effort to optimize the lipid proﬁle of diabetic
atients and, consequently, decrease the prevalence of CVD events
n this population.
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